Drug shortages homepage
Welcome to Drug Shortages Canada, the website for reporting drug shortages and discontinuations in Canada. The Food and Drug Regulations require drug sellers to report when they are not able to meet demand for a product or when they stop selling a product. Information about the website and the regulations can be found on the About & Resources Page.
A shortage means, in respect of a drug, a situation in which the manufacturer to whom a document was issued under subsection C.01.014.2(1) that sets out the drug identification number assigned for the drug is unable to meet the demand for the drug.
A discontinuation means, in respect of a drug, a situation in which the manufacturer to whom a document was issued under subsection C.01.014.2(1) that sets out the drug identification number assigned for the drug, permanently ceases the sale of the drug.
Tier 3 drug shortages are those that have the greatest potential impact on Canada's drug supply and health care system. Impact is based on low availability of alternative supplies, ingredients or therapies. The Tier Assignment Committee (TAC), composed of federal and provincial/territorial governments, healthcare professionals, and industry stakeholders, makes recommendations on the tier assignment of drug shortages. The TAC assessment includes:
- a review of the information gathered on the shortage issue, and
- a thorough discussion on its potential impact and next steps.
Below are the newest and most recently updated Shortage and Discontinuation reports. Alternatively, please visit the Tier 3 page to see current Tier 3 Drug Shortages and associated shortage or discontinuation reports.
!!T3 denotes an actual Tier 3 shortage/discontinuation
!T3 denotes an anticipated Tier 3 shortage/discontinuation
|Brand name||Company Name||Status||Strength||Update||Date Updated||View Report|
|ZYVOXAM 600 MG||PFIZER CANADA ULC||Discontinued||600MG||Updated Report||2022-01-17||103480|
|PMS-CILAZAPRIL||PHARMASCIENCE INC||To be discontinued||1.0MG||Updated Report||2022-01-17||110517|
|TRANSDERM-NITRO 0.6||NOVARTIS PHARMACEUTICALS CANADA INC||Discontinued||0.6MG||Updated Report||2022-01-17||138767|
|DEXTROSE INJECTION USP||ICU MEDICAL CANADA INC||Discontinued||100MG||Updated Report||2022-01-17||141414|
|STERILE WATER FOR INJECTION USP||ICU MEDICAL CANADA INC||Discontinued||100%||Updated Report||2022-01-14||152657|
|!!T3 PROPYL-THYRACIL||PALADIN LABS INC.||Discontinued||50MG||Updated Report||2022-01-13||101076|
|!!T3 PROPYL-THYRACIL||PALADIN LABS INC.||Discontinued||100MG||Updated Report||2022-01-13||107174|
|!!T3 ERWINASE||JAZZ PHARMACEUTICALS FRANCE SAS||Discontinued||10000UNIT||Updated Report||2022-01-13||129623|
|STERILE WATER FOR INJECTION USP||ICU MEDICAL CANADA INC||To be discontinued||100%||New Report||2022-01-12||152615|
|EXTAVIA||NOVARTIS PHARMACEUTICALS CANADA INC||To be discontinued||0.3MG||New Report||2022-01-12||152532|
|TOBRAMYCIN INJECTION, USP||MYLAN PHARMACEUTICALS ULC||Discontinued||40MG||New Report||2022-01-12||152485|
|STATEX SUPPOSITORIES 30MG||PALADIN LABS INC.||Discontinued||30MG||Updated Report||2022-01-11||152444|
|TEVA-AMITRIPTYLINE||TEVA CANADA LIMITED||Discontinued||50MG||New Report||2022-01-07||152378|
|TEVA-AMITRIPTYLINE||TEVA CANADA LIMITED||Discontinued||25MG||New Report||2022-01-07||152375|
|TEVA-AMITRIPTYLINE||TEVA CANADA LIMITED||Discontinued||25MG||New Report||2022-01-07||152351|
|BLES||BLES BIOCHEMICALS INC||Discontinued||500MCG 27MG||Updated Report||2022-01-04||143216|
|ULORIC||TAKEDA CANADA INC||Discontinued||80MG||Updated Report||2022-01-04||144266|
|ATRIPLA||GILEAD SCIENCES, LLC||Discontinued||300MG 200MG 600MG||Updated Report||2022-01-01||144260|
|PNEUMOVAX 23||MERCK CANADA INC||Discontinued||25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG 25MCG||Updated Report||2021-12-18||151479|
|ALPRAZOLAM||SANIS HEALTH INC||Discontinued||0.50MG||Updated Report||2021-12-17||144038|